The panel room settled on a the second floor of the summit hall, tucked behind glass walls that overlooked the river. The lighting was softer here, deliberate, the kind meant to make discussion feel thoughtful instead of adversarial.
A semicircle of chairs waited beneath the stage lights.
Behind them, a screen displayed the title of the afternoon session.
Global Beauty Markets: Innovation, Regulation, and Trust
Rows of industry leaders filled the audience.
Consultants.
Regulators.
Executives who had spent decades deciding which companies survived expansion and which ones stalled quietly at customs.
I recognized several faces from the launch reception earlier.
They recognized me too.
Only now, they looked… curious.
Not hostile.
Not friendly.
Curious in the way analysts study a graph they haven't decided how to interpret yet.
Jinyu and I sat side by side in the front row while the moderator arranged her notes.
"You don't have to answer anything you don't want to," he said quietly.
I glanced at him.
"That would be suspicious."
His mouth twitched.
"True."
Across the room, a tall European consultant leaned toward another panelist, murmuring something that made both of them glance briefly in my direction.
The moderator tapped the microphone.
"Good afternoon, everyone."
The room softened into silence.
"Today we'll be discussing how emerging beauty biotechnology companies are navigating global expansion while maintaining regulatory trust."
She gestured toward the panelists as they took their seats.
A senior regulatory advisor from Brussels.
A market strategist from a major consulting firm.
A veteran executive from a Japanese pharmaceutical conglomerate.
And finally—
"Representing Xuhuang International," she said, smiling politely, "Jiaxin."
Applause followed.
Not enthusiastic.
Measured.
Professional.
I walked onto the stage and took the final chair.
The moderator began with safe questions first.
Global supply chains.
Ingredient transparency.
Testing protocols.
Each panelist answered smoothly, their voices practiced and diplomatic.
The conversation drifted toward market competition.
Then toward regulatory skepticism.
And eventually—
inevitably—
toward Xuhuang.
The consultant from the European firm leaned forward slightly.
"Many analysts attribute Xuhuang's recent breakthroughs primarily to Mr. Xu's scientific leadership," he said, tone pleasant.
Several heads in the audience nodded.
He continued:
"Ms. Jiaxin, your role has been described more as representational within the company's international expansion."
The word hung in the air.
Representational.
A polished version of the article's framing.
The moderator glanced toward me.
"Would you like to respond?"
Every gaze in the room shifted.
Waiting.
Not for an answer.
For confirmation.
I folded my hands loosely in my lap.
"For clarity," I said calmly, "do you mean representational in the sense of branding, or representational in the sense of diplomatic strategy?"
The consultant blinked.
"Brand positioning, primarily."
"Ah."
I nodded slightly.
"In that case, the misunderstanding is understandable."
The room leaned in almost imperceptibly.
"Xuhuang's scientific development and market expansion operate on two separate strategic tracks," I continued.
"Mr. Xu leads the research ecosystem. I lead the distribution architecture."
A few pens paused over notebooks.
"The reason analysts often misinterpret that structure," I added, "is because the second system is less visible."
The moderator tilted her head.
"How so?"
"Because distribution isn't about announcements," I said. "It's about sequencing."
I reached toward the screen behind us.
A chart appeared.
Three regional markets.
Three timelines.
Three completely different entry strategies.
"Southeast Asia," I said, pointing to the first column, "requires regulatory alignment with existing herbal medicine frameworks."
A few audience members nodded.
"Europe requires clinical legitimacy."
Second column.
"Which means slower entry, heavier documentation, and cooperation with legacy certification systems."
Third column.
"Meanwhile the Middle East prioritizes luxury credibility before pharmaceutical credibility."
The consultant who asked the question stopped smiling.
"So when people say Xuhuang's expansion is 'driven by science,'" I said lightly, "they're only seeing half the machine."
Silence followed.
Not awkward.
Evaluative.
The moderator glanced between the charts.
"You negotiated these regional strategies?"
"Yes."
The Japanese executive on the panel leaned forward.
"That would explain why your Southeast Asian distribution moved faster than projected."
I smiled slightly.
"We had the advantage of understanding the regulatory language early."
Across the room, several people were no longer writing.
They were watching.
Differently now.
Not curiosity.
Calculation.
The consultant who had started the exchange cleared his throat.
"Well," he said carefully, "that certainly reframes the perception of your role."
"That tends to happen when the structure becomes visible," I replied.
A quiet ripple of laughter passed through the room.
Polite.
Respectful.
And slightly uncomfortable.
When the panel ended, the applause sounded different.
Still professional.
But heavier.
Like the room had just updated its internal data.
As people stood and began filing out, the same consultant approached the stage.
His smile had changed.
Less indulgent.
"Ms. Jiaxin," he said.
"Yes?"
"You explained that system very clearly."
"Thank you."
He hesitated.
Then admitted, with careful neutrality:
"I believe several of us underestimated the architecture behind your expansion."
I held his gaze.
"That happens often with infrastructure," I said. "People only notice it when it collapses."
He nodded slowly.
Then left.
Outside the room, Jinyu was waiting.
He looked at me for a long moment.
Then said simply:
"Well."
I tilted my head.
"Well?"
"You didn't operate," he said.
"You reorganized the room."
I smiled faintly.
"That was the idea."
For the first time since the article that morning, the narrative around me had shifted.
Not erased.
Not defeated.
Just…
corrected.
And somewhere out there, whoever had started the story would have to decide what to do with the new version.
Because the symbol they had assigned me had just spoken.
And symbols weren't supposed to explain the machine.